1f
12
9
1a
8
20
8
49
16
8
19
1
49
2
8
1b
1d
18
89
3d
1d
2 29
1d
25
3d
Amy Tara Waldman, M.D., M.S.C.E.
70Associate Professor of Neurology at the Children's Hospital of Philadelphia
28
91
3
60
Medical Director, Leukodystrophy Center of Excellence, Children's Hospital of Philadelphia
88
Associate Director of Neurology Gene Therapy, Children's Hospital of Philadelphia
11
Department: Neurology
4
1
b
1d
46
Contact information
51
4
3
3
3
2
4
b
1f
51
Children's Hospital of Philadelphia
1d Division of Neurology
3e 3401 Civic Center Boulevard
Philadelphia, PA 19104
26
1d Division of Neurology
3e 3401 Civic Center Boulevard
Philadelphia, PA 19104
2e
Office: 215-590-1719
32 Fax: 215-590-1771
24
81
32 Fax: 215-590-1771
24
Email:
waldman@chop.edu
12
waldman@chop.edu
13
Education:
21 9 B.A. 16 (Chemistry) c
31 Johns Hopkins University, 1997.
21 9 M.D. 15 (Medicine) c
32 Jefferson Medical College, 2002.
21 d M.S.C.E. 19 (Epidemiology) c
56 Perelman School of Medicine at the University of Pennsylvania, 2011.
c
3
3
21
21 9 B.A. 16 (Chemistry) c
31 Johns Hopkins University, 1997.
21 9 M.D. 15 (Medicine) c
32 Jefferson Medical College, 2002.
21 d M.S.C.E. 19 (Epidemiology) c
56 Perelman School of Medicine at the University of Pennsylvania, 2011.
c
1f
Post-Graduate Training
24 53 Pediatric Intern, Children's Hospital of Philadelphia, 2002-2003.
24 55 Pediatric Resident, Children's Hospital of Philadelphia, 2003-2004.
24 84 Neurology Resident, Children's Hospital of Philadelphia and Hospital of the University of Pennsylvania, 2004-2007.
24 8b Multiple Sclerosis Fellow, Children's Hospital of Philadelphia and Hospital of the University of Pennsylvania, 2007-2009.
c
3
25
24 53 Pediatric Intern, Children's Hospital of Philadelphia, 2002-2003.
24 55 Pediatric Resident, Children's Hospital of Philadelphia, 2003-2004.
24 84 Neurology Resident, Children's Hospital of Philadelphia and Hospital of the University of Pennsylvania, 2004-2007.
24 8b Multiple Sclerosis Fellow, Children's Hospital of Philadelphia and Hospital of the University of Pennsylvania, 2007-2009.
c
17
Certifications
28 43 American Board of Psychiatry and Neurology, 2008.
28 62 American Board of Psychiatry and Neurology - Maintenance of Certification, 2018.
c
3
8d
Permanent link28 43 American Board of Psychiatry and Neurology, 2008.
28 62 American Board of Psychiatry and Neurology - Maintenance of Certification, 2018.
c
2 29
21
1e
1d
24
2b
29
27
23
16d Yamane MLM, Zhao AT, Liu GT, Omari A, Waldman AT, Scoles D: Severe retinal vasculopathy associated with myelin oligodendrocyte glycoprotein antibody optic neuritis in a toddler. Journal of American Association for Pediatric Ophthalmology and Strabismus(104810), Epub ahead of print, Mar 2026.
1b8 Keselman DJ, Small JC, Seneviratne T, McCague S, Kaschak TL, Yum SW, O'Brien A, Brandsema JF, Diamond T, Loomes KM, Lin KY, Wittlieb-Weber CA, Mayer OH, Daniel SG, Waldman AT, Samelson-Jones BJ, Matesanz SE, George LA: Real-world outcomes of delandistrogene moxeparvovec gene therapy: Motor outcomes and emerging safety concerns. Mol Ther 7(34(1)): 123-130, Jan 2026.
f4 Levin D, Levin J, Joung J, Liu GW, Donaher J, Faig W, Waldman AT: Language Skills in Patients With Alexander Disease. Am J Speech Lang Pathol 13(35(1)): 211-225, Jan 2026.
160 Waldman AT, Takanohashi A, Joung JY, Liu GW, Arnold K, Pizzino A, Faig W, Woidill S, Narula S, Vanderver AL: Characterization of Clinical Phenotype to Glial Fibrillary Acidic Protein Concentrations in Alexander Disease. Ann Clin Transl Neurol Jan 2026 Notes: Epub ahead of print.
128 Caplash S, Song H, Waldman A, Ying GS, Kim BJ: Characteristics of Study Design and Statistical Analysis in Optical Coherence Tomography Based Studies of Neurodegeneration. Ophthalmology Science October 2025 Notes: In press.
1c9 Keselman DJ, Small JC, Seneviratne T, McCague S, Kaschak TL, Yum SW, O’Brien A, Brandsema JF, Diamond T, Loomes KM, Lin KY, Wittlieb-Weber CA, Mayer OH, Daniel SG, Waldman AT, Samelson-Jones BJ, Matesanz SE, George LA: Real-World Outcomes of Delandistrogene Moxeparvovec Gene Therapy: Motor Outcomes and Emerging Safety Concerns. Molecular Therapy Epub ahead of print, October 2025.
20c Kotes ER, Woidill S, D'Aiello R, Khan A, McCann J, Ramos M, Gavazzi F, Keller S, Van Haren K, Fatemi A, Eichler F, Bonkowsky J, Fraser J, Emrick L, Sherbini O, Hackett A, Gauna J, Amos D, Goodman J, Fine AS, Nagy A, Lee S, Page N, Schmidt J, Pizzino A, Muirhead K, Bennett M, Waldman A, Shults J, Adang L, Grundmeier R, Vanderver A.: Clinically Important Endpoints in Individuals With Leukodystrophy: A Multisite Study. Ann Child Neurol Soc July 2025.
1e9 Goyne C, Fair AE, Yilmaz D, Race J, Schuette A, Caillier SJ, Aaen GS, Abrams AW, Benson LA, Casper TC, Chitnis T, Gorman MP, Lotze TE, Krupp LB, Mar SS, Ness JM, Rensel M, Rodriguez M, Rose JW, Schreiner TL, Tillema JM, Waldman AT, Wheeler YS, Barcellos LF, Waubant E, Graves JS; as the US Network of Pediatric MS Centers: Epigenetic Aging in Pediatric-Onset Multiple Sclerosis. Neurology 104(12): e213673, Jun 2025.
df Messing A, Waldman AT, Bolt DM: Genotype-Phenotype Association for 14 GFAP Variants in Alexander Disease. Neurology Genetics 11(3): e200270, Jun 2025.
2c
7
1d
1f
Selected Publications
106 Marefi A, Grasso EA, McLendon LA, Narula S, Waldman AT, Hopkins S, Banwell BL: Role of Tocilizumab in Severe CNS Inflammatory Presentations in Children. Neurology 106(8): e214926, Apr 2026.16d Yamane MLM, Zhao AT, Liu GT, Omari A, Waldman AT, Scoles D: Severe retinal vasculopathy associated with myelin oligodendrocyte glycoprotein antibody optic neuritis in a toddler. Journal of American Association for Pediatric Ophthalmology and Strabismus(104810), Epub ahead of print, Mar 2026.
1b8 Keselman DJ, Small JC, Seneviratne T, McCague S, Kaschak TL, Yum SW, O'Brien A, Brandsema JF, Diamond T, Loomes KM, Lin KY, Wittlieb-Weber CA, Mayer OH, Daniel SG, Waldman AT, Samelson-Jones BJ, Matesanz SE, George LA: Real-world outcomes of delandistrogene moxeparvovec gene therapy: Motor outcomes and emerging safety concerns. Mol Ther 7(34(1)): 123-130, Jan 2026.
f4 Levin D, Levin J, Joung J, Liu GW, Donaher J, Faig W, Waldman AT: Language Skills in Patients With Alexander Disease. Am J Speech Lang Pathol 13(35(1)): 211-225, Jan 2026.
160 Waldman AT, Takanohashi A, Joung JY, Liu GW, Arnold K, Pizzino A, Faig W, Woidill S, Narula S, Vanderver AL: Characterization of Clinical Phenotype to Glial Fibrillary Acidic Protein Concentrations in Alexander Disease. Ann Clin Transl Neurol Jan 2026 Notes: Epub ahead of print.
128 Caplash S, Song H, Waldman A, Ying GS, Kim BJ: Characteristics of Study Design and Statistical Analysis in Optical Coherence Tomography Based Studies of Neurodegeneration. Ophthalmology Science October 2025 Notes: In press.
1c9 Keselman DJ, Small JC, Seneviratne T, McCague S, Kaschak TL, Yum SW, O’Brien A, Brandsema JF, Diamond T, Loomes KM, Lin KY, Wittlieb-Weber CA, Mayer OH, Daniel SG, Waldman AT, Samelson-Jones BJ, Matesanz SE, George LA: Real-World Outcomes of Delandistrogene Moxeparvovec Gene Therapy: Motor Outcomes and Emerging Safety Concerns. Molecular Therapy Epub ahead of print, October 2025.
20c Kotes ER, Woidill S, D'Aiello R, Khan A, McCann J, Ramos M, Gavazzi F, Keller S, Van Haren K, Fatemi A, Eichler F, Bonkowsky J, Fraser J, Emrick L, Sherbini O, Hackett A, Gauna J, Amos D, Goodman J, Fine AS, Nagy A, Lee S, Page N, Schmidt J, Pizzino A, Muirhead K, Bennett M, Waldman A, Shults J, Adang L, Grundmeier R, Vanderver A.: Clinically Important Endpoints in Individuals With Leukodystrophy: A Multisite Study. Ann Child Neurol Soc July 2025.
1e9 Goyne C, Fair AE, Yilmaz D, Race J, Schuette A, Caillier SJ, Aaen GS, Abrams AW, Benson LA, Casper TC, Chitnis T, Gorman MP, Lotze TE, Krupp LB, Mar SS, Ness JM, Rensel M, Rodriguez M, Rose JW, Schreiner TL, Tillema JM, Waldman AT, Wheeler YS, Barcellos LF, Waubant E, Graves JS; as the US Network of Pediatric MS Centers: Epigenetic Aging in Pediatric-Onset Multiple Sclerosis. Neurology 104(12): e213673, Jun 2025.
df Messing A, Waldman AT, Bolt DM: Genotype-Phenotype Association for 14 GFAP Variants in Alexander Disease. Neurology Genetics 11(3): e200270, Jun 2025.
2c